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Abstract
Mutations affecting skeletal muscle isoforms of the tropomyosin genes may cause nemaline
myopathy, cap myopathy, core-rod myopathy, congenital fiber-type disproportion, distal
arthrogryposes, and Escobar syndrome. We correlate the clinical picture of these diseases with
novel (19) and previously reported (31) mutations of the TPM2 and TPM3 genes. Included are
altogether 93 families: 53 with TPM2 mutations and 40 with TPM3 mutations. Thirty distinct
pathogenic variants of TPM2 and 20 of TPM3 have been published or listed in the Leiden Open
Variant Database (http://www.dmd.nl/). Most are heterozygous changes associated with
autosomal-dominant disease. Patients with TPM2 mutations tended to present with milder
symptoms than those with TPM3 mutations, DA being present only in the TPM2 group. Previous
studies have shown that five of the mutations in TPM2 and one in TPM3 cause increased Ca2+
sensitivity resulting in a hypercontractile molecular phenotype. Patients with hypercontractile
phenotype more often had contractures of the limb joints (18/19) and jaw (6/19) than those with
nonhypercontractile ones (2/22 and 1/22), whereas patients with the non-hypercontractile
molecular phenotype more often (19/22) had axial contractures than the hypercontractile group
(7/19). Our in silico predictions show that most mutations affect tropomyosin–actin association or
tropomyosin head-to-tail binding.
Keywords
congenital myopathy; genotype–phenotype correlation; TPM2; TPM3; actin; hypercontractile
phenotype
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Introduction
The congenital myopathies are clinically, histologically, and genetically variable
neuromuscular disorders, often caused by mutations in genes encoding sarcomeric proteins
[Wallgren-Pettersson et al., 2011]. These myopathies are defined on the basis of static or
only slowly progressive muscle weakness and a range of structural abnormalities in the
muscle fibers. In recent years, a number of different myopathy entities have been associated
with mutations in one of the two tropomyosin genes, TPM2 and TPM3. Nemaline myopathy
(NM; MIMs #161800, #256030, #605355, #609273, #609284, #609285, #610687, #615348)
is a genetically heterogeneous disorder showing wide clinical variability. It is characterized
by muscle weakness and nemaline (rod) bodies on muscle biopsy [Wallgren-Pettersson et
al., 2004]. NM was described by two separate groups in 1963 [Conen et al., 1963; Shy et al.,
1963]. “Cap myopathy” or “cap disease” (MIMs #609284, #609285) was first characterized
by Fidzianska et al. (1981). The name derives from the cap-like structures located under the
sarcolemma. The first cases of congenital fiber-type disproportion (CFTD; MIM #255310)
was described by Brooke (1973) in patients with hypotrophy of type 1 muscle fibers (Fig. 1).
Arthrogryposis is a very heterogeneous disease category in which distal arthrogryposes
(DA) is one subgroup of dominantly inherited disorders (Fig. 2). Daentl et al. (1974)
described three patients with DA type 1A (MIM #108120). Another form, DA type 2B
(MIM #601680) was first identified by Krakowiak et al. (1997)]. Escobar syndrome is a
nonlethal type of multiple pterygium syndrome (MIM #265000). It was first characterized
by Norum et al. (1969) and associated in one case with NM [Monnier et al., 2009]. Core-rod
myopathy and autosomal-dominanttrismus-pseudocamptodactyly syndrome (DA type 7)
have also recently been associated with TPM2 mutations [Davidson et al., 2013].
The roles of tropomyosins in stabilizing the thin (actin) filament of the sarcomere [Cooper,
2002] and in regulating muscle contraction [Gordon et al., 2000] have been well defined in
skeletal muscle. The tropomyosins exist as coiled-coil homo- or hetero-dimers forming
head-to-tail polymers, running along the length of the actin filament [Phillips et al., 1979;
Matsumura et al., 1983; Holmes et al., 1990; Lin et al., 1997]. They are encoded by four
different genes; TPM1 (MIM # 191010), TPM2 (MIM # 190990), TPM3 (MIM # 191030),
and TPM4 (MIM # 600317) [Pittenger et al., 1994], generating more than 40 different
tropomyosin isoforms due to the use of different promoters or variable intragenic splicing
[Pittenger et al., 1994; Dufour et al., 1998; Cooley and Bergtrom, 2001]. The tropomyosin
genes TPM1, TPM2, and TPM3 encode the skeletal muscle isoforms Tm1 (α-
tropomyosinfast), Tm2 (β-tropomyosin), and Tm3 (α-tropomyosinslow), respectively. TPM1
is mainly expressed in fast muscle fibers and has lower expression in skeletal muscle than in
cardiac muscle. TPM2 is expressed in both slow, and, to a lesser extent, in fast muscle
fibers. TPM3 is expressed exclusively in slow muscle fibers. When both α- and β-
tropomyosins are expressed, α,β-heterodimers are preferentially formed over α-homodimers,
and β-homodimers are rare [Perry, 2001].
Here, we compare the nature and location of novel, and to the best of our knowledge, all
previously described mutations of the TPM2 and TPM3 genes in patients with NM, CFTD,
cap myopathy, core-rod myopathy, DA type 1A, DA type 2B, DA type 7, and NM with
Escobar syndrome to explore the relationships between mutation type and position and the
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phenotypes that arise. Ninety-three families were included in this study: 53 with TPM2
mutations and 40 with TPM3 mutations. Altogether 30 distinct pathogenic variants of TPM2
and 20 of TPM3 have been reported in the literature (including the 14 novel TPM2 and 5
novel TPM3 mutations, a total of 19 mutations reported for the first time in the current
paper). We have also studied previously known and novel phosphorylation sites in
tropomyosin with known patient mutations, and characterized the phosphorylation patterns
in purified proteins containing known patient mutations compared with wild-type (wt)
protein.
Families
Ascertainment
Families reported here for the first time were identified by neuromuscular services in
different countries: Argentina, Australia, Canada, Finland, France, Germany, Israel, Italy,
The Netherlands, UK, and USA. All patients had consented to research or diagnostic genetic
testing. Institutional review board approval was obtained to access patient information, and
written consent was obtained where appropriate.
TPM2
Fifty-three families had mutations of the TPM2 gene. Patients in 13 of the families had been
diagnosed with NM and in five families a diagnosis of cap myopathy was made. CFTD was
the diagnosis in seven families. Ten families had a proband with DA. In one family, a
member had NM with Escobar syndrome. NM and cap myopathy had both been diagnosed
in three families. Affected members of two families with a diagnosis of NM also had
significant fiber-type disproportion. Cap myopathy with fiber-type disproportion had been
diagnosed in two families. One family had DA with unspecified congenital myopathy (CM)
and one with core-rod myopathy. One proband had a diagnosis of CM and affected members
of seven families had no specified diagnosis.
TPM3
Forty families had mutations in the TPM3 gene. Patients in nine families had a diagnosis of
NM and in 20 families, of CFTD with no specific histological hallmarks. Three probands
had been diagnosed with cap myopathy. Two families had members with a diagnosis of NM
and cap myopathy. Probands of four families had CM, and in two there was no specified
diagnosis.
Mutations
Nomenclature of TPM2 and TPM3 Mutations and Database
For the description of sequence variants, we used reference sequence NM 003289.3 for
TPM2 and NM 152263.3 for TPM3. Amino acid coordinates are provided relative to NP
003280.2 and NP_689476.2, respectively. Note that TPM3 mutations are numbered
according to the Human Genome Variation Society recommendations [den Dunnen and
Antonarakis, 2000], meaning the first two ATG codons in the primary cDNA were both
included. TPM2 and TPM3 variants described in the article are listed in the Leiden Open
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Variant Database (http://www.dmd.nl/) at the Center for Human and Clinical Genetics,
Leiden University Medical Center.
Novel Mutations in TPM2 and TPM3
We used Sanger sequencing and dHPLC to identify novel mutations in the TPM2 and TPM3
genes. Including previously published studies, 94 families were included in the study. Of
these, 53 had TPM2 mutations and 41 had TPM3 mutations. There were 30 different
mutations in TPM2 (14 novel mutations we report and 16 previously described) and 20
different mutations in TPM3 (five novel and 15 previously reported) (Tables 1 and 2; Fig.
3). No clinical details were available for 12 TPM2 families and five TPM3 families. None of
these changes were found in the 1000 Genomes Dataset (www.1000genomes.org, accessed
November 2013), nor in the Exome Variant Server, NHLBI Exome Sequencing Project
(ESP) (Seattle, WA) (URL: http://evs.gs.washington.edu/EVS/, accessed November 2013).
Prediction of Pathogenicity of Mutations
PolyPhen-2, version 2.2.2, HumVar option (http://genetics.bwh.harvard.edu/pph2/
index.shtml) [Adzhubei et al., 2010], and FATHMM (functional Analysis through hidden
Markov models), version 2.3 with the prediction algorithm weighted for human mutations
and disease ontology as the option for phenotypic associations (http://
fathmm.biocompute.org.uk) [Shihab et al., 2013] were used to predict the functional effect
of the missense mutations identified in TPM2 and TPM3. Molecular modeling is described
in detail by Memo and Marston (2013).
In TPM2, 17 of the 22 missense mutations were predicted to be possibly or probably
damaging by PolyPhen-2, and FATHMM. However, there were slight discrepancies in the
predictions by the two programs. PolyPhen-2 predicted three mutations (p.Asp2Val,
p.Ala3Gly, and p.Arg91Gly) to be benign, whereas FATHMM predicted the same three
mutations to be damaging. On the other hand, FATHMM predicted the mutation
p.Gln147Pro to be tolerated, whereas PolyPhen-2 predicted the same mutation to be
probably damaging. Both programs predicted two mutations (p.Glu41Lys and p.Asn202Lys)
to be benign or tolerated (Table 1 and Supp. Tables S1 and S2). p.Glu41Lys has, however,
been shown to affect muscle contractility due to decreased calcium sensitivity [Marttila et
al., 2012], and p.Asn202Lys has been hypothesized to affect Tm– Troponin T (TnT)
interactions [Ohlsson et al., 2008].
In TPM3, 16 of the 18 missense mutations were predicted to be possibly or probably
damaging by PolyPhen-2, and 17 were predicted to be damaging by FATHMM. PolyPhen-2
predicted two mutations (p.Leu100Val and p.Arg168His) to be benign, whereas FATHMM
predicted the same mutations to be damaging. On the other hand, FATHMM predicted the
mutation p.Thr253Lys to be tolerated, whereas PolyPhen-2 predicted the same mutation to
be possibly damaging (Table 2 and Supp. Tables S3, S4, and S5). Our analysis shows that
both PolyPhen-2 and FATHMM were able to correctly predict more than 80% of the
pathogenic Tm mutations (82.5% for PolyPhen-2 and 85% for FATHMM).
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Recurrent Mutations in TPM2 and TPM3
Two recurrent mutations were found in TPM2. The first is p.Lys7del, which was found in 10
families [Davidson et al., 2013; Mokbel et al., 2013; present study, see Table 1]. The second
one is p.Glu139del, which has been reported in five families [Lehtokari et al., 2007; Clarke
et al., 2009; Tasca et al., 2013; present study, see Table 1].
One mutational hotspot was identified in TPM3. The p.Arg168 residue was mutated in 21
families. The recurrent mutation p.Arg168His was present in 12 families [Durling et al.,
2002; Penisson-Besnier et al., 2007; Clarke et al., 2008; De Paula et al., 2009; Lawlor et al.,
2010; present study, see Table 2 and Supp. Table S6]. Eight families had the p.Arg168Cys
mutation [Clarke et al., 2008; present study, see Table 2 and Supp. Table S6] and one family
had the p.Arg168Gly mutation [Clarke et al., 2008; see Table 2.].
Clinical Relevance
Tropomyosins are actin-binding, coiled-coil proteins expressed in all eukaryotic cells. Their
major function in skeletal muscle is to stabilize actin and to regulate actin–myosin
interactions by limiting access to myosin-binding sites along the major groove of the actin
filament [Gunning et al., 2005]. The tropomyosin α-helical coiled coil consists of
heptapeptide repeats (abcdefg) where the a and d residues are generally nonpolar and form
the interhelical interface (or core) of the double-stranded structure [Perry, 2001].
CM phenotypes can be classified into two types: those that are characterized by congenitally
weak muscles and those with congenitally normal or hypercontractile muscles (e.g., DA).
Contractility is the major factor that is altered by mutations in contractile proteins such as
tropomyosin. The classification of these disorders is a challenge because a single mutation
shared between patients can cause a range of phenotypes. This was seen in patients in two
recently published papers on the Lys7del mutation [Davidson et al., 2013; Mokbel et al.,
2013]. Within the 10 families described, the variability in phenotype is quite remarkable,
complicating the recognition of any definite clinical and histological phenotype–genotype
correlation.
NM, cap myopathy, and CFTD are closely related entities with largely overlapping clinical
features, whereas DA and Escobar syndrome may be seen as more distinct clinical entities
with less clinical overlap with other disorders within the group. Distal contractures are,
however, seen in all these disease groups. The age at presentation did not appear to differ
between the TPM2 and TPM3 groups. In both, the majority presented perinatally or in
infancy, a smaller number in childhood, with delayed motor milestones, and few in
adulthood.
Nine of the patients with TPM2 mutations presented with distal arthrogryposis, whereas
none of the patients with TPM3 mutations presented with this feature. This may be due to
Tm2 being expressed earlier during development than Tm3 [Muthuchamy et al., 1993].
Patients with the recurrent deletion mutation Lys7del in the 5′-end of the gene presented
with jaw contractures, camptodactyly (2/10) or core-rod myopathy (1/10), contractures
(4/10), and difficulty in opening the mouth (4/10) [Davidson et al., 2013; Mokbel et al.,
2013]. Nemaline bodies were also present in patients with a diagnosis of DA type 7 (3/3),
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exemplifying the overlap between phenotypic characteristics of these disease entities (Supp.
Tables S1 and S2).
In most families in the present series, the disease-causing mutations were heterozygous, and
the mode of inheritance dominant in 89 families. Of the dominant cases, 43 were due to de
novo mutations. Few TPM3 mutations were homozygous and these were all found in the
beginning or at the end of the gene. Most recessive mutations were nonsense mutations
changing an amino acid to a stop codon, yielding a truncated protein or changing the stop
codon to give rise to a longer protein. The dominant ones tended to be missense mutations or
in-frame deletions. Among patients with TPM2 mutations, only one, a patient with NM
andpterygia, was homozygous for a recessive mutation. There was one case of mosaicism
associated with a heterozygous TPM2 mutation. In the TPM3 group, four families showed
the recessive mode of inheritance, and there was one case of probable mosaicism. Thus,
mosaicism needs to be taken into account in genetic counseling for disorders caused by
mutations in either gene.
Type 1 fiber predominance and hypotrophy were common features for all disease entities
except for the case of Escobar syndrome. Fiber size disproportion appeared to be consistent
among all patients with TPM3 mutations. Type 1 hypotrophy is to be expected in patients
with TPM3 mutations because of the exclusive expression of Tm3 in type 1 fibers [Perry,
2001], but small type 1 fibers were common also in the group with TPM2 mutations, despite
the expression of Tm2 in both fiber types.
Cap structures and nemaline bodies appeared to be more frequent in biopsies taken at older
ages (in three families). This may be explained by the disease process leading to
accumulation of sarcomeric protein inclusions over time. Most of the biopsies in CFTD
cases had been taken at very young ages (5 months, 6 months, 8 months, 1 year, 14 months,
16 months, 2 years, 11 years, and 29 years). This raises the question of whether the
diagnosis of these patients would change if additional biopsies were taken later in life. Such
situations have been encountered in a number of CM cases, for example, in one patient with
CFTD and cap myopathy caused by a mutation in TPM2. In the biopsy taken at the age of 11
years, only fiber type disproportion was noted, whereas in the later biopsy taken at the age
of 33 years, cap structures were obvious [Lehtokari et al., 2007]. Caps were more commonly
observed in patients with TPM2 mutations than in patients with TPM3 mutations (10/41 vs.
5/35; Fig. 4), but the small sample size and the possibility of sampling bias at muscle biopsy
hinder any firm conclusion that this should be a significant difference. It has been suggested
that cap disease might be considered an early stage or variant of NM [Tajsharghi et al.,
2007]. The variable observations of caps and/or nemaline bodies in families and even in
individual patients over time [Lehtokari et al., 2007; Tajsharghi et al., 2007] support the
concept of cap myopathy being a subcategory of NM.
Patients with hypercontractile molecular phenotypes based on structural analysis of the
actin–tropomyosin interface [Marston et al.,2013] (marked by # in the Tables 1 and 2, Supp.
Tables S1–S4) more often have contractures of the limb joints (18/19) and jaw (6/19) than
those who do not have this type of mutation (2/22 and 1/22). Patients with the
nonhypercontractile molecular phenotypes much more often (19/22) have axial contractures
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(usually scoliosis, but also rigid spine) than the hypercontractile group (7/19). Presentation
was early in both groups, so molecular hypercontractility does not, as has been indicated for
patients with the Lys7del mutation in previous studies [Davidson et al., 2013; Memo and
Marston, 2013; Mokbel et al., 2013] always cause delayed onset of muscle weakness (Supp.
Table S1). Only one hypercontractile molecular phenotype was found in TPM3 in this study,
p.Lys169Glu [Memo and Marston, 2013]. Three are known altogether (unpublished data).
Our results indicate that NM caused by mutations in TPM2 usually has a milder presentation
than NM caused by mutations in TPM3 (TPM2: 10 NM cases, one adult onset, TPM3: 10
NM cases, four severe) (Table 3). Recessive disease caused by mutations in these genes
appears mostly to be severe. There is no other clear correlation between the type of mutation
and the clinical phenotype. For TPM2, this was also stated by Tajsharghi et al. (2012) in a
recent review.
Biological Relevance
Causative Mutations and Actin Association
In the current models [Perry, 2001; Brown et al., 2005; Li et al., 2011; Memo and Marston,
2013], it is proposed that tropomyosin has a sevenfold repeated amino acid sequence motif
that corresponds to the seven actin monomers covered by one tropomyosin. Each motif is
subdivided into α- and β-zones. In the relaxed “Off” state, tropomyosin forms contacts with
actin through positively charged basic residues in the N-terminal part of an α-zone and
acidic residues on the C-terminal side of an α-zone. Ca2+ regulation is imposed on actin–
tropomyosin by the troponin complex that switches actin–tropomyosin between the “On”
and “Off” conformational states. Thus, mutations in tropomyosin potentially can cause
muscle dysfunction leading to myopathy through a variety of mechanisms, including effects
on formation of dimers, end-to-end interactions, actin binding, and the regulatory interaction
with troponin.
Molecular Modeling
Molecular modeling is described in detail by Memo and Marston (2013).
Tropomyosin interaction sites with actin in the “Off” state were precisely mapped by Li et
al. (2011). Actin p.Asp25 is predicted to interact with all seven tropomyosin actin-binding
repeats. A TPM2 mutation at one of these tropomyosin interaction sites is p.Lys128Glu and
similar TPM3 mutations are p.Arg91Pro/Cys, the hotspot p.Arg168Cys/Gly/His, and
p.Arg245Gly/Ile (Fig. 5). Interestingly, gain-of-function mutations that increase contractility
are located in the amino acid next to the Tm actin-binding site: p.Lys7del, p.Lys49del, and
p.Arg91Gly in TPM2 and p.Lys169Glu in TPM3 [Memo and Marston, 2013]. Actin amino
acids 147, 326, and 328 interact with two acidic amino acids in each actin-binding repeat of
tropomyosin separated by two to three amino acids at the end of an α-zone. Disease-causing
mutations are found affecting only the first acidic amino acid and they are both gain-of-
function mutations: TPM2 p.Glu139del and p.Glu181Lys [Li et al., 2011; Ochala et al.,
2012; Memo and Marston, 2013].
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In the “On” state, tropomyosin shifts in position relative to the actin filament and myosin
contacts are formed [Behrmann et al., 2012]. The “On” state tropomyosin–actin contacts are
less well defined and tropomyosin may simply be pushed into its position by strong myosin–
actin binding. Overall, fewer disease-causing mutations are adjacent to the proposed “On”
state tropomyosin– actin contacts: the TPM2 mutations p.Asp14Val, p.Glu139del,
p.Glu218del, and the TPM3 mutations p.Leu100Met/Val (Tables 1 and 2; Fig. 5; Supp.
Table S5). The other main protein that interacts with tropomyosin is TnT. Of the known
TPM2 mutations, p.Tyr261Cys, and in TPM3, p.Met9Arg are involved in the interaction
with TnT according to Murakami’s structure of TPM2 [Murakami et al., 2008] (Fig. 6).
Head-to-tail polymerization of tropomyosin is required for actin binding, and has a role is in
actin filament assembly, and for the regulation of actin–myosin contraction [Murakami et
al., 2008]. The mutations p.Ala3Gly, p.Lys7del in TPM2 and p.Ala4Val, p.Met9Arg, and
p.Stop285Ser/Asn in TPM3 are found at the overlapping region involved in head-to-tail
polymerization (Fig. 3).
We hypothesize that the charge changes inherent in most hypercontractile mutations would
destabilize the “Off” state and favor the equilibrium toward the “On” state, thus accounting
for the higher Ca2+ sensitivity as was demonstrated for the ACTA1 p.Lys326Asn mutation
[Orzechowski et al., 2013]. This would be the case with the TPM2 mutations p.Lys7del,
p.Lys49del, p.Arg91Gly, p.Glu139del, and p.Glu181Lys, and the TPM3 mutation
p.Lys169Glu. This seems to correlate with hypercontractile or DA phenotypes that are
p.Lys7del, p.Arg91Gly, p.Arg133Trp, and p.Glu181Lys. Congenital muscle weakness
correlates with loss-of-function at the molecular level. These mutations are not at the
interface of the “Off” state but have an opposite charge change to the gain-of-function
mutations and are in a location that could stabilize the “Off” state relative to the “On” state,
which may account for the loss-of-function. On the other hand, alteration of the
tropomyosin–troponin interface could also have this effect. Mutations shown to be
associated with decreased Ca2+ sensitivity include TPM2-Glu41Lys, TPM2-Glu117Lys,
TPM3-Arg168His, and TPM3-Arg245Gly.
In this study, we discuss altogether 30 mutations in TPM2 and 20 mutations in TPM3. More
than half of them (18/30 for TPM2 and 14/20 for TPM3) are located in α-zones, which
contain residues interacting with actin in the “Off” state. In addition, three (p.Asp2Val,
p.Ala3Gly, and p.Lys7del) of the TPM2 and four (p.Ala4Val, p.Met8Arg, p.Stop285Ser, and
p.Stop285Asn) of the TPM3 mutations are located in the tropomyosin overlapping region
(Fig. 3). These regions are essential for tropomyosin function such as actin binding and
polymerization. The TPM3-Arg168His and TPM2-null mutations were found to severely
reduce the proportion of strong myosin cross-bridges bound to actin filaments at
submaximal Ca2+ concentrations and thus to depress force production. The TPM2-
Glu181Lys mutant was found to have enhanced Ca2+ sensitivity and force production
[Ochala et al., 2012]. Most mutations are in conserved areas of TPM2 and TPM3. Only five
mutations (TPM2-Asp2Val, TPM3-Gln31Stop, TPM2-Glu41Lys, TPM2-Leu143Pro, and
TPM3-Thr252Lys) are in sites where sequence differs between the genes. Four of the amino
acids varying between tropomyosins (TPM2-Asp2Val, TPM2-Glu41Lys, TPM2-Leu143Pro,
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and TPM3-Thr252Lys) are substituted by similar amino acids, for example, acidic by
another acidic one.
Identification of Novel Phosphorylation Sites in Tm2
Phosphorylation has been shown to modify tropomyosin function: it enhances head-to-tail
interaction of neighboring tropomyosin dimers, increases binding to TnT and slows
relaxation of Ca2+-activated force [Heeley et al., 1989; Hayley et al., 2008; Nixon et al.,
2013]. To elucidate a potential role of tropomyosin phosphorylation on pathogenesis, mass
spectrometry analyses were performed on purified recombinant tropomyosin, both Tm2 and
proteins containing known patient mutations (p.Glu41Lys, p.Lys49del, p.Glu117Lys,
p.Glu139del, and p.Gln147Pro). We found four known phosphorylation sites (p.Thr53,
p.Thr252, p.Thr282, and p.Ser283) that were present in both the wt and the mutated proteins
[Dai et al., 2007; Huttlin et al., 2010]. In addition, we identified four novel phosphorylation
sites (p.Thr79, p.Thr108, p.Ser158, and p.Ser206) (Supp. Table S7). The previously
unknown phosphorylation sites are situated in the mid region of Tm2 around the mutational
hotspot in or near the fourth α-zone (Fig. 3). In all cases examined, the phosphorylation
patterns were identical between the wt and the mutated proteins, indicating that changes in
phosphorylation patterns are not the main cause of disease for the mutations studied. Also,
no patient mutations have been found in the phosphorylated residues in Tm2 and Tm3.
Interestingly, in Tm3, only the previously known p.Ser283 was found to be phosphorylated,
which corresponds to p.Ser283 in Tm2.
Conclusions
In this report, we have compiled, to the best of our knowledge, all previously reported and
novel mutations of TPM2 and TPM3. Altogether we analyzed 27 mutations causing an
amino acid change and 3 mutations predicted to affect splicing inTPM2 and 20 mutations in
TPM3. Patients with TPM2 mutations tended to present with milder symptoms than those
with TPM3 mutations, DA being present only in the TPM2 group. Recessive disease was
usually more severe than the dominantly inherited forms. Fiber-type disproportion was
consistent in the TPM3 group and was also common with mutations of TPM2. Patients with
hypercontractile molecular phenotypes more often had contractures of the limb joints and
jaw than those with nonhypercontractile molecular phenotypes, whereas those with no
hypercontractility more commonly had spinal deformities or rigidity. No difference was
found in the age of onset.
We show that most mutations affect actin association (18/30 in TPM2 and 13/20 in TPM3),
resulting in the clinical and histological pictures of NM, cap myopathy, core-rod myopathy,
CFTD, CM, DA, and Escobar syndrome with myopathy. Six mutations cause increased Ca2+
sensitivity resulting in hypercontractile phenotypes. Among the remaining mutations, all
five so far tested caused decreased Ca2+ sensitivity. Three of the TPM2 and four of the
TPM3 mutations were located in the tropomyosin overlapping region affecting head-to-tail
binding. We report four novel phosphorylation sites in β-tropomyosin. Although
phosphorylation is known to be linked to tropomyosin–actin association, we found no
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mutations in phosphorylated residues, nor altered phosphorylation patterns in purified
tropomyosin proteins containing known patient mutations.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Histological characteristics of NM, cap myopathy, and CFTD. Histology images showing
the range of abnormalities in skeletal muscle that can arise with mutations in tropomyosin.
A–C: NM. In TPM2, NM (A: p.K7del mutation) rods are often randomly scattered. In
TPM3, NM (B: p.M9R), rods are confined to type 1 fibers that are usually hypotrophic. C:
Nemaline bodies on electron microscopy. D–F: CFTD due to mutations in TPM3D and E:
ATPase (4.3) showing the consistent difference in size between type 1 fibers (dark) and type
2 fibers (pale). Type 1 fiber predominance is common (D) but a range is seen (E). D:
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Increased internalized nuclei in large (type 2) fibers in an adult CFTD patient with the TPM3
p.L100M mutation. G–J: Cap myopathy due to the TPM2 p.Glu139del mutation. Caps are
most reliably seen on ATPase stains (H) but are sometimes visible on H&E stains (G) or
oxidative stains. I and J: Electron microscopy of a typical cap structure.
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Figure 2.
Distal arthrogryposis patient. Little girl with distal arthrogryposis and suspected myopathy.
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Figure 3.
Sequence comparison of Tm1, Tm2, and Tm3 and Tm2–Tm3 dimer with disease-causing
mutations and phosphorylation sites. A: Schematic presentation of Tm2 and Tm3 dimers
with disease-causing mutations (shown in red and above the molecules), α-zones (purple),
and overlapping regions (separated by green lines in N- and C-terminal ends of the
molecules). Phosphorylation sites are marked underneath the molecules. Novel mutations/
phosphorylation sites are shown in yellow. The figure was created using the PyMol software
(http://www.pymol.org) and the Protein Databank structure 1C1GA. B: Sequence
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comparison of Tm1, Tm2, and Tm3. Mutations are indicated in the sequence by red dots. In
the Tm3 protein amino acid sequence (P06753), the initiation codons have been processed,
thus the nomenclature is different compared with that in other figures. Stars underneath the
sequences indicate conserved amino acids, and dots show the sites where sequences diverge.
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Figure 4.
A pie chart showing histopathological characteristics in biopsies from patients with
mutations in the TPM2 and TPM3 genes. Abbreviations: NM, nemaline bodies; Cap, Cap
structures; and CFTD, fiber size disproportion.
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Figure 5.
On-state actin−tropomyosin contacts and disease mutations. The Tm2 (β-Tm) sequence and
the Tm3 (γ-Tm) sequence divided into seven quasi-repeats and α- and β-bands as defined by
Mclachlan and Stewart (1976). The purple circles highlight residues interacting with actin
Asp25; the orange circles highlight the residues interacting with actin R147, K326, and
K328 as defined by Li et al. (2010). The Tm2 mutations are indicated in blue boxes; the
Tm3 mutations are indicated in green boxes. The mutations increasing Ca2+-sensitivity are
written in red, whereas those decreasing it are in black.
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Figure 6.
Tropomyosin end–end overlap and interactions of tropomyosin with TnT. Tropomyosin
end–end overlap (one to nine and 277–284, gray boxes) and interactions of tropomyosin
with TnT based on the model of Murakami et al. (2008). Mutations in overlap zone are
shown as gray circles; pink outline TPM1 (cardiomyopathy), blue outline TPM2. Only a few
mutations are involved in contacts with TnT (green) in this region of tropomyosin. TPM2
Y261C is next to A262, M9R is supposed to bind to F86 in TnT, and K15N (TPM1) is
supposed to bind with TnT Q79.
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Table 3
Summary of Clinical Findings in TPM2 and TPM3
Clinical observation TPM2 TPM3
Age of onset Majority perinatally or
in infancy, small
number in childhood
and few in adulthood
Majority perinatally or
in infancy, small
number in childhood
and few in adulthood
Distal arthrogrypos is Nine patients None
Fiber size disproportion 29 families 35 families
NM Milder presentation
(10 NM cases, one adult onset)
More severe
presentation (10 NM cases, four severe)
Patients with hypercontractile
molecular phenotypes have
more often contractures
than others
Hypercontractile:
contractures of limb
joints (18/19) and
jaw (6/19)
Hypercontractile:
contractures of limb
joints (18/19) and
jaw (6/19)
Others: contractures of
limb joints (2/22)
and jaw (1/22)
Others: contractures of
limb joints (2/22)
and jaw (1/22)
Summary of clinical findings in TPM2 and TPM3.
NM, nemaline myopathy.
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